BridgeBio Pharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
BridgeBio Pharma, Inc. (BBIO) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of -$3.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2026-08-10
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.67M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$2.51M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$1.77M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$2.19M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2025 was -$8.01M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2024 was -$7.58M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2023 was -$10.05M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2022 was -$3.47M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.67M 10-Q · filed 2026-08-10 | -$6.19M 10-Q · filed 2026-08-10 | -$7.96M derived: sum of 3 quarters · filed 2026-08-10 | -$10.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.51M 10-Q · filed 2026-05-07 | -$4.28M derived: sum of 2 quarters · filed 2026-05-07 | -$6.48M derived: sum of 3 quarters · filed 2026-05-07 | -$8.33M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$3.97M derived: sum of 2 quarters · filed 2026-02-24 | -$5.82M derived: sum of 3 quarters · filed 2026-08-10 | -$8.01M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$2.19M 10-Q · filed 2025-10-29 | -$4.05M derived: sum of 2 quarters · filed 2026-08-10 | -$6.24M 10-Q · filed 2025-10-29 | -$8.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.85M 10-Q · filed 2026-08-10 | -$4.04M 10-Q · filed 2026-08-10 | -$6.38M derived: sum of 3 quarters · filed 2026-08-10 | -$8.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$2.19M 10-Q · filed 2026-05-07 | -$4.53M derived: sum of 2 quarters · filed 2026-05-07 | -$6.74M derived: sum of 3 quarters · filed 2026-05-07 | -$8.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.55M derived: sum of 2 quarters · filed 2026-02-24 | -$6.64M derived: sum of 3 quarters · filed 2026-02-24 | -$7.58M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$2.21M 10-Q · filed 2025-10-29 | -$4.30M derived: sum of 2 quarters · filed 2025-10-29 | -$5.25M 10-Q · filed 2025-10-29 | -$7.43M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$2.09M 10-Q · filed 2025-08-05 | -$3.03M 10-Q · filed 2025-08-05 | -$5.21M derived: sum of 3 quarters · filed 2026-02-24 | -$7.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$944.00K 10-Q · filed 2025-04-29 | -$3.12M derived: sum of 2 quarters · filed 2026-02-24 | -$5.61M derived: sum of 3 quarters · filed 2026-02-24 | -$8.42M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.67M derived: sum of 2 quarters · filed 2026-02-24 | -$7.47M derived: sum of 3 quarters · filed 2026-02-24 | -$10.05M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$2.49M 10-Q · filed 2024-11-12 | -$5.29M derived: sum of 2 quarters · filed 2024-11-12 | -$7.87M 10-Q · filed 2024-11-12 | -$10.85M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$2.80M 10-Q · filed 2024-08-01 | -$5.38M 10-Q · filed 2024-08-01 | -$8.36M derived: sum of 3 quarters · filed 2025-02-20 | -$11.21M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$2.58M 10-Q · filed 2024-05-02 | -$5.55M derived: sum of 2 quarters · filed 2025-02-20 | -$8.41M derived: sum of 3 quarters · filed 2025-02-20 | -$1.11M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$5.83M derived: sum of 2 quarters · filed 2025-02-20 | $1.46M derived: sum of 3 quarters · filed 2025-02-20 | -$3.47M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$2.85M 10-Q · filed 2023-11-02 | $4.44M derived: sum of 2 quarters · filed 2023-11-02 | -$490.00K 10-Q · filed 2023-11-02 | -$5.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $7.30M 10-Q · filed 2023-08-03 | $2.36M 10-Q · filed 2023-08-03 | -$2.74M derived: sum of 3 quarters · filed 2024-02-22 | -$7.82M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$4.93M 10-Q · filed 2023-05-04 | -$10.04M derived: sum of 2 quarters · filed 2024-02-22 | -$15.12M derived: sum of 3 quarters · filed 2024-02-22 | -$20.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$10.19M derived: sum of 2 quarters · filed 2024-02-22 | -$15.91M derived: sum of 3 quarters · filed 2024-02-22 | -$23.91M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$5.08M 10-Q · filed 2022-11-03 | -$10.81M derived: sum of 2 quarters · filed 2022-11-03 | -$18.81M 10-Q · filed 2022-11-03 | -$33.85M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$5.73M 10-Q · filed 2022-08-04 | -$13.73M 10-Q · filed 2022-08-04 | -$28.77M derived: sum of 3 quarters · filed 2023-02-23 | -$43.08M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$8.00M 10-Q · filed 2022-05-05 | -$23.05M derived: sum of 2 quarters · filed 2023-02-23 | -$37.35M derived: sum of 3 quarters · filed 2023-02-23 | -$52.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$15.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$29.35M derived: sum of 2 quarters · filed 2023-02-23 | -$44.53M derived: sum of 3 quarters · filed 2023-02-23 | -$56.76M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$14.31M 10-Q · filed 2021-11-04 | -$29.49M derived: sum of 2 quarters · filed 2021-11-04 | -$41.72M 10-Q · filed 2021-11-04 | -$52.41M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$15.18M 10-Q · filed 2021-08-05 | -$27.41M 10-Q · filed 2021-08-05 | -$38.10M derived: sum of 3 quarters · filed 2022-02-25 | -$38.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$12.23M 10-Q · filed 2021-05-06 | -$22.93M derived: sum of 2 quarters · filed 2022-02-25 | -$23.61M derived: sum of 3 quarters · filed 2022-02-25 | -$31.98M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$11.38M derived: sum of 2 quarters · filed 2022-02-25 | -$19.75M derived: sum of 3 quarters · filed 2022-02-25 | -$28.00M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$684.00K 10-Q · filed 2020-11-05 | -$9.05M derived: sum of 2 quarters · filed 2020-11-05 | -$17.30M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$8.37M 10-Q · filed 2020-08-11 | -$16.62M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$8.25M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$38.70M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | -$13.27M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |